Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 25, 2020 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Completes Targeted Enrollment in Pivotal Phase 3 Study for CDKL5 Deficiency Disorder

RADNOR, Pa., Feb. 25, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
February 24, 2020 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals to Participate at Three Upcoming Investor Healthcare Conferences

RADNOR, Pa., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
February 14, 2020 16:05 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RADNOR, Pa., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative...
February 03, 2020 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals to Present Ganaxolone EEG Clinical Data in Status Epilepticus at the American Clinical Neurophysiology Society 2020 Annual Meeting

RADNOR, Pa., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and...
January 13, 2020 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Provides Business Outlook for 2020

Enrollment on-track for CDKL5 Deficiency Disorder Phase 3 readout Q3 2020 Two additional late-stage clinical trials planned to initiate in 2020 Company presentation and live webcast at 38th Annual...
January 07, 2020 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals to Present at the 38th Annual J.P. Morgan Global Healthcare Conference

RADNOR, Pa., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of...
December 13, 2019 16:43 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

RADNOR, Pa., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative...
December 13, 2019 16:01 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Announces Closing of $70 Million Public Offering of Common Stock and Concurrent Private Placement Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

RADNOR, Pa., Dec. 13, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced the closing of an underwritten public offering of 32,200,000...
December 12, 2019 07:30 ET | Source: Marinus Pharmaceuticals, Inc.

Marinus Pharmaceuticals Appoints Elan Ezickson to Board of Directors

RADNOR, Pa., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or “Company”), a pharmaceutical company dedicated to the development of innovative therapeutics...
December 11, 2019 10:30 ET | Source: Marinus Pharmaceuticals, Inc.

Corrected Press Release: Marinus Pharmaceuticals Announces Pricing of $65 Million Public Offering of Common Stock and Concurrent Private Placement

RADNOR, Pa., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced the pricing of an underwritten public offering of 28,000,000...